Trial Profile
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Rivoceranib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ASPC
- 25 Jan 2020 Trial design presented at the 2020 Gastrointestinal Cancers Symposium
- 18 Sep 2018 Planned End Date changed from 1 Mar 2020 to 1 Aug 2020.
- 18 Sep 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2020.